The US Food and Drug Administration has added a heart-protection indication to Eli Lilly's Mounjaro (tirzepatide). The label now covers reducing the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes at high risk of these events. FDA signed the approval on 27 August 2026, based on the SURPASS-CVOT trial.
The decision has been circulating again in recent days, but it is not new: Lilly announced it on 28 August 2026 and listed it among its regulatory highlights in its third-quarter results on 29 October. This article sets out what the FDA actually approved, what the trial showed and did not show, how Europe has handled the same data, and where Mounjaro stands for patients in Ireland.
- New US indication: "to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events" (FDA label, 08/2026).
- Approval date: 27 August 2026 (FDA supplement approval letter, NDA 215866/S-044 and S-045); Lilly announced it on 28 August.
- Evidence: SURPASS-CVOT, 13,299 adults with type 2 diabetes and established cardiovascular disease, comparing Mounjaro with dulaglutide (Trulicity) rather than placebo.
- Result: hazard ratio 0.92 (95.3% CI 0.83 to 1.01) for first major cardiovascular event. Non-inferior to dulaglutide; superiority was not established.
- Europe: the EU product information was updated with the SURPASS-CVOT results in June 2026, but as study data in the SmPC rather than as a separate stand-alone indication.
- Ireland: the NCPE has recommended that Mounjaro for type 2 diabetes be considered for reimbursement only if cost-effectiveness can be improved. We found no published HSE reimbursement decision.
1. What the FDA approved
Mounjaro was first approved in the US in 2022 to improve blood sugar control in adults with type 2 diabetes, alongside diet and exercise. The FDA later extended that use to children aged 10 and over. The August 2026 decision adds a second, separate indication: reducing the risk of major adverse cardiovascular events, defined as cardiovascular death, non-fatal heart attack or non-fatal stroke, in adults with type 2 diabetes who are at high risk of those events.
The FDA approval letter, addressed to Lilly's regulatory affairs team in Indianapolis, covers two supplements. Supplement S-044 updates the prescribing information and medication guide with the SURPASS-CVOT results and adds the new indication. It also revises a warning about diabetic retinopathy complications in patients with a history of the eye condition, based on the same trial. Supplement S-045 confirms that the 2.5 mg dose can be used for ongoing blood sugar control, not only as a starting dose. Lilly had filed the applications on 27 October and 5 November 2025.
Lilly describes Mounjaro as the first and only dual GIP and GLP-1 receptor agonist with a cardiovascular risk-reduction indication. Kenneth Custer, president of Lilly Cardiometabolic Health, said in the company's announcement that Lilly "set a higher bar by testing Mounjaro against a GLP-1 medicine with proven cardiovascular benefit". The approval applies to Mounjaro, the diabetes brand. It does not change the label of Zepbound, Lilly's tirzepatide brand for weight management in the US.
2. What SURPASS-CVOT showed
SURPASS-CVOT (ClinicalTrials.gov NCT04255433) was a Phase 3, event-driven, randomised, double-blind trial. Adults aged 40 or over with type 2 diabetes, established cardiovascular disease, an HbA1c between 7.0% and 10.5% and a BMI of at least 25 were assigned to once-weekly Mounjaro (up to 15 mg) or once-weekly dulaglutide 1.5 mg. The average participant was 64 years old and had lived with diabetes for 15 years. Median follow-up was 210.1 weeks, about four years. The full results were published in the New England Journal of Medicine in December 2025.
Dulaglutide was chosen as the comparator because it already carries a cardiovascular indication from its own outcomes trial, REWIND. That makes SURPASS-CVOT a tougher test than a placebo-controlled study, but it also means the result is framed as "at least as good as" an active heart-protective drug.
| Outcome | Mounjaro | Dulaglutide | Hazard ratio (95% CI) |
|---|---|---|---|
| Heart attack, stroke or CV death (primary) | 803 (12.1%) | 863 (13.0%) | 0.92 (0.83 to 1.01)* |
| Cardiovascular death | 367 (5.5%) | 409 (6.2%) | 0.89 (0.77 to 1.02) |
| Non-fatal heart attack | 292 (4.4%) | 310 (4.7%) | 0.93 (0.80 to 1.09) |
| Non-fatal stroke | 215 (3.2%) | 221 (3.3%) | 0.97 (0.80 to 1.16) |
| Death from any cause | 567 (8.5%) | 670 (10.1%) | 0.84 (0.75 to 0.94) |
*95.3% confidence interval for the primary endpoint. Components and death from any cause were not controlled for multiple testing, so they are supportive rather than confirmatory.
The headline number, an 8% lower rate of the main cardiovascular composite, is the figure Lilly uses. Statistically, the trial met its non-inferiority test (p=0.007 in the US label; the EU product information gives a non-inferiority margin of 1.05), but the upper end of the confidence interval crosses 1.0, so the FDA label states plainly that "superiority to dulaglutide was not established". The 16% lower rate of death from any cause is eye-catching, but because it sat outside the trial's formal testing hierarchy it should be read with caution. Lilly also cited an indirect comparison with REWIND suggesting a larger effect versus placebo. That analysis is indirect and does not appear in the indication.
Safety was broadly in line with what was already known. Gastrointestinal effects such as nausea and diarrhoea were the most common side effects, mostly mild to moderate and more frequent while the dose was being increased.
3. How Europe has handled the same data
Mounjaro has held an EU marketing authorisation since 15 September 2022 (EMA product number EMEA/H/C/005620). The EMA's procedural record shows a Type II variation (EMA/VR/0000310637) with an outcome dated 25 June 2026 that updated sections 4.1, 4.4, 4.8 and 5.1 of the Summary of Product Characteristics with the final SURPASS-CVOT results, together with the package leaflet.
The European approach differs from the American one in form. The current EU product information does not list cardiovascular risk reduction as a separate indication. Instead, the diabetes indication in section 4.1 points readers to section 5.1 for results on cardiovascular events, and section 5.1 describes SURPASS-CVOT, stating that the result "demonstrated the benefit of cardiovascular risk reduction with tirzepatide" and that superiority over dulaglutide was not achieved. This is a common pattern for diabetes medicines in the EU, where outcome trial data are often added to the clinical studies section rather than as a new indication. Lilly says submissions based on SURPASS-CVOT are under review in other markets, but has not listed them.
4. What it means for Ireland
Because Mounjaro is authorised centrally, the updated EU product information applies in Ireland. Doctors here can already see the SURPASS-CVOT results in the Irish SmPC. What the FDA decision does not change is access through the public system.
The National Centre for Pharmacoeconomics completed its assessment of Mounjaro for type 2 diabetes (HTA ID 24003) in early 2026. It recommended that tirzepatide "be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments". Lilly is seeking reimbursement under the Community Drugs Schemes, and the final decision rests with the HSE. We found no published HSE decision to reimburse Mounjaro for type 2 diabetes. A separate application for weight management (HTA ID 24024) is also with the HSE, as we reported in our coverage of the HSE's Mounjaro funding deliberations. Readers who want to compare the two drugs in the trial can use our Mounjaro vs Trulicity comparison.
The industrial link is significant. Lilly says it has operated in Ireland since 1981 and employs more than 4,000 people across manufacturing in Kinsale, Co Cork, and Limerick, and its Global Business Solutions centre in Little Island, Cork. Its Kinsale campus makes active pharmaceutical ingredients for Lilly medicines worldwide, including synthetic peptides since 2022. In September 2024 Lilly announced USD 800 million for Kinsale "to meet demand for Lilly's latest diabetes and obesity treatments" and USD 1 billion for its Limerick biologics site, which Lilly says is on track to make medicine in 2026. Lilly has not publicly confirmed which Irish site, if any, makes tirzepatide. More detail is on our Eli Lilly Ireland company page.
This article reports a regulatory decision and is not medical advice. Anyone with questions about their diabetes or heart medicines should speak to their GP, pharmacist or specialist.
Frequently Asked Questions
Is the FDA heart-risk approval for Mounjaro new?
No. The FDA approved the new indication on 27 August 2026 and Lilly announced it the following day. Some recent reports have presented it as fresh news, but the decision is about two months old.
Did Mounjaro beat Trulicity on heart outcomes?
Not formally. Mounjaro had an 8% lower rate of heart attack, stroke or cardiovascular death than dulaglutide (Trulicity), which met the test for non-inferiority. The difference was not large enough to prove superiority.
Does Mounjaro have the same heart indication in Ireland and the EU?
The SURPASS-CVOT results were added to the EU product information in June 2026, so they apply in Ireland. However, the EU label presents them as trial data under the diabetes indication rather than as a separate cardiovascular indication like the new US wording.
Outlook
The US label change gives Mounjaro a formal cardiovascular claim of the kind that GLP-1 medicines such as dulaglutide already carry, strengthening Lilly's position in diabetes care. In Europe the data are already in the product information, so the open questions for Ireland are about price and access rather than evidence. The things to watch are any HSE decision on the two NCPE assessments, whether other regulators follow the FDA's stand-alone indication wording, and how Lilly's Irish expansion in Kinsale and Limerick progresses.
Sources
- US Food and Drug Administration, Supplement approval letter, NDA 215866/S-044 and S-045 (Mounjaro), 27 August 2026
- US Food and Drug Administration, Mounjaro prescribing information, revised 08/2026
- Eli Lilly and Company, FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes, 28 August 2026
- Eli Lilly and Company, Third-quarter 2026 results (Form 8-K exhibit), 29 October 2026
- European Medicines Agency, Mounjaro EPAR, product information and procedural steps, last updated 18 August 2026
- National Centre for Pharmacoeconomics, Tirzepatide (Mounjaro) HTA ID 24003, 9 February 2026
- ClinicalTrials.gov, SURPASS-CVOT, NCT04255433
- Eli Lilly Ireland, Lilly in Ireland and About Lilly Kinsale, accessed 2 November 2026
- Eli Lilly and Company via PR Newswire, Lilly expands manufacturing footprint in Ireland with USD 1.8 billion investment, 12 September 2024
- AJMC, FDA expands tirzepatide label to reduce cardiovascular risk in T2D, 28 August 2026
Cover image: AI-generated illustration of the Mounjaro KwikPen and carton. It is not a photograph of the real product or its packaging.
